Search
for
Sort by
Research 61–90 of 1000+
- Unique Cutaneous Reaction to Second- and Third-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
- Several Selective Protein Kinase C Inhibitors Including Procyanidins Promote Hair Growth
- Protein Kinase C Epsilon Signals Ultraviolet Light-induced Cutaneous Damage and Development of Squamous Cell Carcinoma Possibly Through Induction of Specific Cytokines in a Paracrine Mechanism¶
- Foxn1 promotes keratinocyte differentiation by regulating the activity of protein kinase C
- Inhibition of the development of metastatic squamous cell carcinoma in protein kinase C epsilon transgenic mice by alpha-difluoromethylornithine accompanied by marked hair follicle degeneration and hair loss.
- Adverse cutaneous reactions to the new second-generation tyrosine kinase inhibitors (dasatinib, nilotinib) in chronic myeloid leukemia
- Comparative efficacy of oral Janus kinase inhibitors and biologics in adult alopecia areata: A systematic review and Bayesian network meta‐analysis
- The role of Janus kinase inhibitors in the treatment of alopecia areata: A systematic review
- Skin-specific regulation of SREBP processing and lipid biosynthesis by glycerol kinase 5
- Janus kinase inhibition for the treatment of refractory frontal fibrosing alopecia: A case series and review of the literature
- A Case of Inflammatory Nonscarring Alopecia Associated With the Tyrosine Kinase Inhibitor Nilotinib
- Janus Kinase Inhibitors in Dermatology: Part 1 — General Considerations and Applications in Vitiligo and Alopecia Areata
- Unexpected Hair Regrowth in a Patient with Longstanding Alopecia Universalis During Treatment of Recalcitrant Dermatomyositis with the Janus Kinase Inhibitor Ruxolitinib
- Janus Kinase Inhibitors for Alopecia Areata
- Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase‐4 inhibitors
- Janus kinase inhibitors: An innovative treatment for alopecia areata
- Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata
- Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis
- Induction of hair growth by skin irritants and its relation to skin protein kinase C isoforms
- Various Applications of Tofacitinib and Ruxolitinib (Janus Kinase Inhibitors) in Dermatology and Rheumatology: A Review of Current Evidence and Future Perspective
- Exploring the efficacy of baricitinib in treating alopecia areata after failed Janus kinase inhibitor therapy
- Janus kinase inhibitors for alopecia areata
- Protein kinase Akt2/PKBβ is involved in blastomere proliferation of preimplantation mouse embryos
- Treatment of alopecia areata with the janus kinase inhibitor upadacitinib: A retrospective cohort study
- Janus Kinase Inhibitors against Other Biological Treatments in Alopecia Areata
- Repigmentation of leukoderma in a piebald patient associated with a novel c-KIT gene mutation, G592E, of the tyrosine kinase domain
- 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)
- A review of Janus kinase inhibitor use in scarring alopecia
- At the crossroads of 2 alopecias: Androgenetic alopecia pattern of hair regrowth in patients with alopecia areata treated with oral Janus kinase inhibitors
- Off-label use of biologics and janus kinase (JAK) inhibitors for scarring alopecias: a narrative review